SEC Form SC 13G/A filed by Cue Biopharma Inc. (Amendment)
$CUE
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2024 | $6.00 | Buy | Jefferies |
| 6/26/2023 | $10.00 | Outperform | Oppenheimer |
| 11/21/2022 | $7.00 | Overweight | Piper Sandler |
| 1/13/2022 | $20.00 | Buy | H.C. Wainwright |
| 1/3/2022 | $28.00 | Buy | Craig Hallum |
8-K - Cue Biopharma, Inc. (0001645460) (Filer)
S-8 - Cue Biopharma, Inc. (0001645460) (Filer)
S-3 - Cue Biopharma, Inc. (0001645460) (Filer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
Jefferies initiated coverage of Cue Biopharma with a rating of Buy and set a new price target of $6.00
Oppenheimer resumed coverage of Cue Biopharma with a rating of Outperform and set a new price target of $10.00
Piper Sandler initiated coverage of Cue Biopharma with a rating of Overweight and set a new price target of $7.00
Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a precision immuno-engineering company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced the transition of its board as the Company continues its strategic growth and transformation to support late clinical stage capabilities and activities. Effective May 29, 2026, four independent directors, Jill Broadfoot, P
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that Shao-Lee Lin, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 3:10 p.m. EDT in New York City. A live audio webcast and replay of the presentation will be available through Cue Biopharma's Investor Relations website. The webcast will be archived for 90 days. About Cue BiopharmaCue Biopharma (NASDAQ:CUE) is a clinical stage therapeutics company focused on advancing a portfolio o
Enhanced the company's portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a bifunctional IL-2 and TGF-B program targeting autoimmune diseaseStrengthened the company's balance sheet and ability to fund anticipated cash needs with a $30 million private placement and received a $7.5 million milestone payment under a collaboration and license agreement Appointed Shao-Lee Lin, M.D., Ph.D., as President, CEO and Board Director to lead continued growth and transformation into a clinical-stage company. BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical stage therapeuti
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
4 - Cue Biopharma, Inc. (0001645460) (Issuer)
3 - Cue Biopharma, Inc. (0001645460) (Issuer)
Daniel Camardo, former CEO and executive commercial leader with a track record of successful launches joins the board Viola Meehan, former CFO with broad experience in governance, strategic finance and executive leadership joins the board BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a precision immuno-engineering company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced the transition of its board as the Company continues its strategic growth and transformation to support late clinical stage capabilities and activities. Effective May 29, 2026, four independent directors, Jill Broadfoot, P
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated results in 2H 2026 from Ascendant Health-led Phase 2 study in chronic spontaneous urticaria Transaction establishes Cue Biopharma as a clinical-stage company with a robust portfolio of therapies targeting functional cures for immunological disorders BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells
BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Shao-Lee Lin, M.D., Ph.D., as Chief Executive Officer, President and Director. Dr. Lin will succeed Lucinda Warren, Interim President and Chief Executive Officer. "Shao-Lee's exceptional track record progressing breakthrough therapies from concept to clinic, combined with her disciplined approach to leading companies through growth, will be a massive step as we advance C
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET. Conference Call and Webcast DetailsTuesday, April 15 at 4:30 p.m. ET Investors:1-844-826-3035International Investors:1-412-317-5195Conference ID:10199037Webcast Link:https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572 The live and archived webcast will also b
BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company's approach to enhance near-term shareholder value by refocusing resourc
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, April 8, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company's website. The Company will provide a corporate update highlighting measurable progress advancing its lead clinical oncology programs, CUE-101 and CUE-102, its lead preclinical autoimmune program CUE-401 partnered with Ono Pharmaceutical, as well as additional au
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)
SC 13G - Cue Biopharma, Inc. (0001645460) (Subject)